Eloralintide Guide
Eli Lilly
Complete guide to Eloralintide (LY3841136) — Eli Lilly
What Is Eloralintide?
Eloralintide (development code LY3841136) is Eli Lilly's investigational selective amylin receptor agonist. Unlike GLP-1 drugs such as Semaglutide (Wegovy/Ozempic) or dual agonists like Tirzepatide (Mounjaro/Zepbound), Eloralintide works through an entirely different hormonal pathway.
Amylin is a peptide hormone naturally co-secreted with insulin by the pancreatic beta-cells in response to food intake. It plays a central role in controlling how fast your stomach empties, suppressing post-meal glucagon release, and signaling fullness to the brain. By selectively targeting the amylin 1 receptor (AMY1R), Eloralintide amplifies these natural satiety signals to reduce calorie intake and promote significant weight loss.
This makes Eloralintide a distinct and complementary tool in the metabolic medicine landscape, potentially working alongside GLP-1 therapies rather than simply competing with them. Eli Lilly is already studying Eloralintide in combination with tirzepatide. Track your current protocol in Shotlee while this science evolves.
The Amylin Mechanism
Phase 2 Clinical Results (48 Weeks)
Side Effects
Eloralintide vs Current Options
All listed medications can be tracked in the free Shotlee app. Build your baseline data now and compare how different drug classes — including amylin agonists — perform for your body over time.
Vital Protocol FAQs
Guide FAQs
Complete guide to Eloralintide (LY3841136) — Eli Lilly
Yes. Shotlee supports tracking Eloralintide doses, side effects, and health metrics. It is free to use.
PubMed, ClinicalTrials.gov, and the FDA website are the most reliable sources for current Eloralintide research and regulatory updates. Peer-reviewed journals including the New England Journal of Medicine, The Lancet, and JAMA publish the most impactful clinical trial results. This guide is updated regularly to reflect the latest available evidence. Use Shotlee to track your personal protocol outcomes alongside the published research.
Before starting Eloralintide, establish baseline measurements including body weight, waist circumference, blood pressure, and relevant lab work with your healthcare provider. Download Shotlee and begin logging your baseline metrics at least one week before starting treatment. This pre-treatment data provides the comparison point needed to objectively evaluate your treatment response over time. Additionally, discuss potential side effects and management strategies with your prescriber so you are prepared for the initial adaptation phase.
Evidence-based lifestyle modifications that complement Eloralintide protocols include: maintaining adequate protein intake (1.2-1.6g per kg body weight per day) to preserve lean mass, performing resistance training two to three times per week, staying well hydrated with at least eight glasses of water daily, prioritizing seven to nine hours of quality sleep, managing stress through regular physical activity or mindfulness practices, and eating smaller more frequent meals during dose titration phases. Track these lifestyle factors alongside your Eloralintide data in Shotlee to identify which combinations drive your best results.
Track Your Eloralintide Protocol in Shotlee
Free dose logging, side effect tracking, and health metric monitoring for your complete protocol.